UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5794-5799

2009

Volltextzugriff (PDF)

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

Journal of clinical oncology, 2008-12, Vol.26 (35), p.5748-5754

2008

Volltextzugriff (PDF)

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Journal of clinical oncology, 2004-03, Vol.22 (5), p.909-918

2004

Volltextzugriff (PDF)

BRAF Mutations in Metanephric Adenoma of the Kidney

European urology, 2012-11, Vol.62 (5), p.917-922

2012

Volltextzugriff (PDF)

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1029-1039

2021

Volltextzugriff (PDF)

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

Journal of clinical oncology, 2018-02, Vol.36 (4), p.391-398

2018

Volltextzugriff (PDF)

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1020-1028

2021

Volltextzugriff (PDF)

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

Journal of immunotherapy (1997), 2005-09, Vol.28 (5), p.488

2005

Volltextzugriff (PDF)

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

Journal of clinical oncology, 2015-06, Vol.33 (18), p.2013-2020

2015

Volltextzugriff (PDF)

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2292-2298

2008

Volltextzugriff (PDF)

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

Urologic oncology, 2013-11, Vol.31 (8), p.1788-1793

2013

Volltextzugriff (PDF)

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

Journal of clinical oncology, 2015-07, Vol.33 (21), p.2384-2391

2015

Volltextzugriff (PDF)

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4066-4076

2015

Volltextzugriff (PDF)

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

Journal of translational medicine, 2009-07, Vol.7 (1), p.68-68, Article 68

2009

Volltextzugriff (PDF)

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

Journal of clinical oncology, 2014-11, Vol.32 (33), p.3771-3778

2014

Volltextzugriff (PDF)

Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

Journal of clinical oncology, 2001-08, Vol.19 (16), p.3622-3634

2001

Volltextzugriff (PDF)

Long-Term Use of Nonsteroidal Anti-inflammatory Drugs Decreases the Risk of Cutaneous Melanoma: Results of a United States Case–Control Study

Journal of investigative dermatology, 2011-07, Vol.131 (7), p.1460-1468

2011

Volltextzugriff (PDF)

Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1196-1202

2010

Volltextzugriff (PDF)

Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases

The American journal of dermatopathology, 2016-09, Vol.38 (9), p.687-689

2016

Volltextzugriff (PDF)

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma

Urologic oncology, 2011-11, Vol.29 (6), p.756-763

2011

Volltextzugriff (PDF)

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12

Journal of immunotherapy, 2001-01, Vol.24 (1), p.91-98

2001

Volltextzugriff (PDF)

Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687)

Anti-cancer drugs, 1999-02, Vol.10 (2), p.245-248

1999

Volltextzugriff (PDF)

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

Journal of clinical oncology, 1994-08, Vol.12 (8), p.1553-1560

1994

Volltextzugriff (PDF)

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

Journal of clinical oncology, 1990-10, Vol.8 (10), p.1650-1656

1990

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

KollektionAUTh Library subscriptions: Taylor & Francis Journals

Zeitschrift / SerieMelanoma Research

ThemaImmunotherapy

KollektionIngentaConnect

KollektionIngentaConnect Journals

ThemaAged

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(39)
Life Sciences & Biomedicine
(38)
Middle Aged
(38)
Science & Technology
(38)
Male
(37)
Adult
(28)
Oncology
(28)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Aged, 80 And Over
(16)
Treatment Outcome
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Kidney Neoplasms - Pathology
(9)
Melanoma - Drug Therapy
(9)
Original Reports
(9)
Tumors
(9)
Carcinoma, Renal Cell - Drug Therapy
(8)
Drug Administration Schedule
(8)

13 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

BRAF Mutations in Metanephric Adenoma of the Kidney

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)

Long-Term Use of Nonsteroidal Anti-inflammatory Drugs Decreases the Risk of Cutaneous Melanoma: Results of a United States Case–Control Study

Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery

Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12

Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687)

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

Aktive Filter

Suchergebnisse filtern